EE03528B1 - Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine - Google Patents

Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine

Info

Publication number
EE03528B1
EE03528B1 EE9700175A EE9700175A EE03528B1 EE 03528 B1 EE03528 B1 EE 03528B1 EE 9700175 A EE9700175 A EE 9700175A EE 9700175 A EE9700175 A EE 9700175A EE 03528 B1 EE03528 B1 EE 03528B1
Authority
EE
Estonia
Prior art keywords
preparation
valaciclovir hydrochloride
valaciclovir
hydrochloride
Prior art date
Application number
EE9700175A
Other languages
English (en)
Estonian (et)
Other versions
EE9700175A (et
Inventor
Howard Carter Barry
Muse Partin Jane
Gregory Varlashkin Peter
Augustus Winnike Richard
Bayne Grubb William
Alan Conway Gregory
George Lake Philip
Michael Skinner David
James Whatrup David
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03528(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of EE9700175A publication Critical patent/EE9700175A/xx
Publication of EE03528B1 publication Critical patent/EE03528B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
EE9700175A 1995-01-20 1996-01-19 Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine EE03528B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (2)

Publication Number Publication Date
EE9700175A EE9700175A (et) 1998-02-16
EE03528B1 true EE03528B1 (et) 2001-10-15

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700175A EE03528B1 (et) 1995-01-20 1996-01-19 Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine

Country Status (40)

Country Link
US (1) US6107302A (no)
EP (1) EP0804436B1 (no)
JP (1) JP3176633B2 (no)
KR (1) KR100376074B1 (no)
CN (1) CN1049893C (no)
AP (1) AP662A (no)
AR (1) AR002270A1 (no)
AT (1) ATE302777T1 (no)
AU (1) AU702794B2 (no)
BG (1) BG63393B1 (no)
BR (1) BR9606768A (no)
CA (1) CA2210799C (no)
CY (1) CY2531B1 (no)
CZ (1) CZ297065B6 (no)
DE (1) DE69635106T2 (no)
DK (1) DK0804436T3 (no)
EA (1) EA000364B1 (no)
EE (1) EE03528B1 (no)
ES (1) ES2248806T3 (no)
FI (1) FI973063A (no)
GB (1) GB9501178D0 (no)
GE (1) GEP20001940B (no)
HR (1) HRP960024B1 (no)
HU (1) HU222993B1 (no)
IL (1) IL116831A (no)
IN (1) IN182468B (no)
IS (1) IS2268B (no)
NO (1) NO315558B1 (no)
NZ (1) NZ298851A (no)
OA (1) OA10499A (no)
PL (1) PL182175B1 (no)
RO (1) RO118693B1 (no)
RS (1) RS49518B (no)
SI (1) SI0804436T1 (no)
SK (1) SK285329B6 (no)
TR (1) TR199700656T1 (no)
UA (1) UA46001C2 (no)
UY (1) UY25779A1 (no)
WO (1) WO1996022291A1 (no)
ZA (1) ZA96449B (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CA2278474A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
HUP0500753A3 (en) * 2001-09-07 2006-05-29 Teva Pharma Crystalline forms of valacyclovir hydrochloride
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
ES2270172T3 (es) * 2002-10-16 2007-04-01 Teva Pharmaceutical Industries Ltd. Procedimiento para reducir alcoholes residuales en hidrocloruro de valaciclovir cristalino.
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
CA2552560A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP2008504255A (ja) * 2004-06-30 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド 結晶塩酸バラシクロビル中の残留アルコールを低減する方法
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
US7846937B2 (en) * 2005-05-25 2010-12-07 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20110235A1 (es) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
RU2569749C2 (ru) * 2007-08-17 2015-11-27 Бёрингер Ингельхайм Интернациональ Гмбх Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ES2157259T3 (es) * 1993-06-10 2001-08-16 Rolabo Sl Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos.
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
IL116831A (en) 1998-10-30
CA2210799C (en) 2008-06-10
DK0804436T3 (da) 2005-12-27
HRP960024B1 (en) 2005-08-31
HUP9801836A2 (hu) 1999-05-28
YU3396A (sh) 1998-12-23
IN182468B (no) 1999-04-17
FI973063A (fi) 1997-09-18
AU4453996A (en) 1996-08-07
CZ229497A3 (en) 1997-12-17
HUP9801836A3 (en) 1999-06-28
US6107302A (en) 2000-08-22
GB9501178D0 (en) 1995-03-08
EA199700124A1 (ru) 1997-12-30
DE69635106D1 (de) 2005-09-29
ES2248806T3 (es) 2006-03-16
FI973063A0 (fi) 1997-07-18
CY2531B1 (en) 2006-04-12
AP662A (en) 1998-08-19
ATE302777T1 (de) 2005-09-15
IS4527A (is) 1997-07-15
NO973326D0 (no) 1997-07-18
CN1179159A (zh) 1998-04-15
EP0804436B1 (en) 2005-08-24
HU222993B1 (hu) 2004-01-28
IS2268B (is) 2007-07-15
EE9700175A (et) 1998-02-16
ZA96449B (en) 1996-08-07
MX9705462A (es) 1997-10-31
RS49518B (sr) 2006-10-27
AP9701058A0 (en) 1997-10-31
TR199700656T1 (xx) 1998-03-21
BG101833A (en) 1998-04-30
UA46001C2 (uk) 2002-05-15
EP0804436A1 (en) 1997-11-05
KR19980701525A (ko) 1998-05-15
IL116831A0 (en) 1996-05-14
SK96597A3 (en) 1998-02-04
GEP20001940B (en) 2000-02-05
PL321326A1 (en) 1997-12-08
JP3176633B2 (ja) 2001-06-18
SI0804436T1 (sl) 2006-02-28
SK285329B6 (sk) 2006-11-03
NZ298851A (en) 1999-01-28
NO315558B1 (no) 2003-09-22
NO973326L (no) 1997-09-16
DE69635106T2 (de) 2006-06-08
UY25779A1 (es) 2000-08-21
WO1996022291A1 (en) 1996-07-25
JPH11503718A (ja) 1999-03-30
OA10499A (en) 2002-04-10
KR100376074B1 (ko) 2003-06-02
RO118693B1 (ro) 2003-09-30
EA000364B1 (ru) 1999-06-24
CZ297065B6 (cs) 2006-08-16
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
PL182175B1 (pl) 2001-11-30
AU702794B2 (en) 1999-03-04
CA2210799A1 (en) 1996-07-25
BR9606768A (pt) 1997-12-30
AR002270A1 (es) 1998-03-11
HRP960024A2 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
EE03528B1 (et) Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
CY2013003I1 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
DE59510981D1 (de) Bohrfutter
DE59510926D1 (de) Bohrfutter
DE69612854D1 (de) Spannfutter
DE19581725T1 (de) Spannfutter
EE03568B1 (et) Bensimidasooli derivaadid, nende valmistamismeetod ja kasutamine
FI980023A (fi) Sienilääke, siihen soveltuva yhdiste, menetelmä niiden valmistamiseksi ja menetelmä niiden käyttämiseksi
DE69528980D1 (de) Bohrfutter
BR9611020A (pt) Conjunto de dispensador de dois tubos adaptador para uso no mesmo e processo para produzir um dispensador de dois tubos
DE69514175D1 (de) Spannfutter
DE69605743D1 (de) Druckverfahren
DE69520558D1 (de) Halogenierungsverfahren
BR9501980A (pt) Copolimeros,processo para sua preparação
DK1044183T3 (da) Amineringsproces
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
DE69603161D1 (de) Druckverfahren
EE03351B1 (et) Meetod lerkanidipiinhüdrokloriidi valmistamiseks
DK0726265T3 (da) 10-Aminoaliphatyl-dibenz[b,f]oxepiner med antineurodegenerativ virkning
DK0727416T3 (da) Substituerede benzensulfonylurinstoffer og -thiourinstoffer, og fremgangsmåde til deres fremstilling, deres anvendelse som
FI941914A (fi) 2-amino-4-kinoliinidihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö
NO972239L (no) Ny replikasjonsprosess
BR9506969A (pt) Cames múltiplos

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110119